S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
We investigated the efficacy of S-Adenosyl-L-Methionine (SAMe) augmentation in patients with treatment-resistant depressive disorder (TRD). Thirty-three outpatients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressa...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/204649 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563037736796160 |
|---|---|
| author | Domenico De Berardis Stefano Marini Nicola Serroni Gabriella Rapini Felice Iasevoli Alessandro Valchera Maria Signorelli Eugenio Aguglia Giampaolo Perna Anatolia Salone Giuseppe Di Iorio Giovanni Martinotti Massimo Di Giannantonio |
| author_facet | Domenico De Berardis Stefano Marini Nicola Serroni Gabriella Rapini Felice Iasevoli Alessandro Valchera Maria Signorelli Eugenio Aguglia Giampaolo Perna Anatolia Salone Giuseppe Di Iorio Giovanni Martinotti Massimo Di Giannantonio |
| author_sort | Domenico De Berardis |
| collection | DOAJ |
| description | We investigated the efficacy of S-Adenosyl-L-Methionine (SAMe) augmentation in patients with treatment-resistant depressive disorder (TRD). Thirty-three outpatients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressants were treated openly with fixed dose of SAMe (800 mg) for 8 weeks, added to existing medication. The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression (HAM-D). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on HAM-D total score and a CGI-I score of 1 or 2 at endpoint were considered responders; remission was defined as a HAM-D score ≤7. Secondary outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Sheehan Disability Scale (SDS). At 8 weeks, a significant decrease in HAM-D score was observed with response achieved by 60% of the patients and remission by 36%. Also a statistically significant reduction in SHAPS and SDS was observed. Our findings indicate that SAMe augmentation may be effective and well tolerated in stage II TRD. However, limitations of the present study must be considered and further placebo-controlled trials are needed. |
| format | Article |
| id | doaj-art-91c11c8dfd724a3395d32c3e92ff8921 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-91c11c8dfd724a3395d32c3e92ff89212025-02-03T01:21:17ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/204649204649S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind StudyDomenico De Berardis0Stefano Marini1Nicola Serroni2Gabriella Rapini3Felice Iasevoli4Alessandro Valchera5Maria Signorelli6Eugenio Aguglia7Giampaolo Perna8Anatolia Salone9Giuseppe Di Iorio10Giovanni Martinotti11Massimo Di Giannantonio12Chair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyChair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyNational Health Service (NHS), Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, p.zza Italia 1, ASL 4, 64100 Teramo, ItalyNational Health Service (NHS), Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, p.zza Italia 1, ASL 4, 64100 Teramo, ItalyLaboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine “Federico II”, 80131 Naples, ItalyHermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, 63100 Ascoli Piceno, ItalyInstitute of Psychiatry, University of Catania, 95121 Catania, ItalyInstitute of Psychiatry, University of Catania, 95121 Catania, ItalyHermanas Hospitalarias, FoRiPsi, Department of Clinical Neurosciences, Villa San Benedetto Menni, Albese con Cassano, Como, ItalyChair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyChair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyChair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyChair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, ItalyWe investigated the efficacy of S-Adenosyl-L-Methionine (SAMe) augmentation in patients with treatment-resistant depressive disorder (TRD). Thirty-three outpatients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressants were treated openly with fixed dose of SAMe (800 mg) for 8 weeks, added to existing medication. The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression (HAM-D). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on HAM-D total score and a CGI-I score of 1 or 2 at endpoint were considered responders; remission was defined as a HAM-D score ≤7. Secondary outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Sheehan Disability Scale (SDS). At 8 weeks, a significant decrease in HAM-D score was observed with response achieved by 60% of the patients and remission by 36%. Also a statistically significant reduction in SHAPS and SDS was observed. Our findings indicate that SAMe augmentation may be effective and well tolerated in stage II TRD. However, limitations of the present study must be considered and further placebo-controlled trials are needed.http://dx.doi.org/10.1155/2013/204649 |
| spellingShingle | Domenico De Berardis Stefano Marini Nicola Serroni Gabriella Rapini Felice Iasevoli Alessandro Valchera Maria Signorelli Eugenio Aguglia Giampaolo Perna Anatolia Salone Giuseppe Di Iorio Giovanni Martinotti Massimo Di Giannantonio S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study The Scientific World Journal |
| title | S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study |
| title_full | S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study |
| title_fullStr | S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study |
| title_full_unstemmed | S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study |
| title_short | S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study |
| title_sort | s adenosyl l methionine augmentation in patients with stage ii treatment resistant major depressive disorder an open label fixed dose single blind study |
| url | http://dx.doi.org/10.1155/2013/204649 |
| work_keys_str_mv | AT domenicodeberardis sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT stefanomarini sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT nicolaserroni sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT gabriellarapini sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT feliceiasevoli sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT alessandrovalchera sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT mariasignorelli sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT eugenioaguglia sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT giampaoloperna sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT anatoliasalone sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT giuseppediiorio sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT giovannimartinotti sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy AT massimodigiannantonio sadenosyllmethionineaugmentationinpatientswithstageiitreatmentresistantmajordepressivedisorderanopenlabelfixeddosesingleblindstudy |